Condition
Photodermatoses
Photodermatoses are skin conditions in which light, usually sunlight, triggers or worsens a reaction, from common polymorphous light eruption to rare inherited disorders. The evidence is strongest for afamelanotide, with trials in erythropoietic protoporphyria finding people gained much more pain-free time in sunlight, and for nicotinamide, which helps cells repair UV damage. Beta-carotene and fern extract have moderate support, but the afamelanotide results apply to that one rare condition.
Sources: PMID 26132941; PMID 26979527
- Supplements studied
- 1
- Medicines and peptides
- 1
- Graded outcomes
- 3
- Trials
- 1
- People studied
- 57
Evidence by supplement
- Strong
- Moderate
- Limited
- Very limited
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Polymorphic Light Eruptions | Improves (the measure goes up) | 3 studies | 57 people | |||
Studies that measured polymorphic light eruptions
| ||||||
Prescription medicines and peptides studied, for context
Afamelanotide
- Pain-Free Sun Exposure Time: changes; see studies
- Quality of Life (EPP): improves
- Phototoxic Reactions: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Pain-Free Sun Exposure Time 69.4 vs 40.8 hours median (US trial); 6.0 vs 0.8 hours (EU trial) | Changes; see studies | Large effect | 10 studies | |||
| Quality of Life (EPP) Improved outdoor activity participation | Improves (the measure goes up) | Moderate effect | 10 studies | |||
| Phototoxic Reactions 77 vs 146 reactions over 9 months treatment | Improves (the measure goes down) | Large effect | 3 studies |
Key findings
- Pain-Free Sun Exposure TimeChanges; see studies
- Quality of Life (EPP)Improves (the measure goes up)
- Phototoxic ReactionsImproves (the measure goes down)
The Photodermatoses (Sun Sensitivity) Support protocol
2 primary supplements · 4 supporting supplements
- Nicotinamide (Vitamin B3)500 mg twice daily
- Beta-Carotene25–180 mg daily (dose depends on condition)
Shop the evidence-backed picks
Fullscript collectionSkin: evidence-graded picksOpen on Fullscript
The collection holds the supplements we grade A or B for its theme, in third-party tested products where the catalog has them. It opens in our Fullscript store. You can look through it without signing in; Fullscript asks for a free account to order.
We earn from purchases made in our Fullscript store, and links to Fullscript, iHerb or Thorne carry our referral, so we may earn a commission at no extra cost to you. Grades come from the research and never change based on what we earn. Full disclosure
Studies cited
35 studies from PubMed
- German Cohort Observational Study to Investigate the Short- and Long-Term Safety and Clinical Effectiveness of Afamelanotide 16 mg (SCENESSE) in Patients With Erythropoietic Protoporphyria (EPP)
- Afamelanotide in managing cutaneous phototoxicity in erythropoietic protoporphyria: a Scottish perspective.
- Treatment Advances in Vitiligo: An Updated Review.
- Afamelanotide in protoporphyria and other skin diseases: a review
- Bridging Molecular Mechanism and Clinical Practice in Vitiligo Treatment: An Updated Review.
- A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo.
- Afamelanotide in protoporphyria and other skin diseases: a review.
- A feasibility and safety study of afamelanotide in acute stroke patients - an open label, proof of concept, phase iia clinical trial.
- Afamelanotide Is Associated with Dose-Dependent Protective Effect from Liver Damage Related to Erythropoietic Protoporphyria.
- Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria
- Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria.
- Immunopathogenesis and management of polymorphic light eruption.
- Beyond pigmentation: signs of liver protection during afamelanotide treatment in Swiss patients with erythropoietic protoporphyria, an observational study.
- Afamelanotide in combination with NB-UVB for treatment of vitiligo in an Asian population
- Current and innovative emerging therapies for porphyrias with hepatic involvement.
- Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review.
- Afamelanotide: A Review in Erythropoietic Protoporphyria
- Afamelanotide for Erythropoietic Protoporphyria
- Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial
- Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria.
- Evaluation of the immunogenicity of the synthetic α-melanocyte-stimulating hormone (α-MSH) analogue afamelanotide ([Nle4-D-Phe7]-α-MSH, Scenesse®) in erythropoietic protoporphyria patients by ELISA detecting both anti-afamelanotide and anti-α-MSH antibodies.
- Afamelanotide: first-in-class melanocortin 1 receptor agonist
- A bioassay for the detection of neutralizing antibodies against the α-melanocyte stimulating hormone analog afamelanotide in patients with erythropoietic protoporphyria
- A review and update on melanocyte stimulating hormone therapy: afamelanotide.
- A one-year open-label safety study of afamelanotide in erythropoietic protoporphyria
- Afamelanotide, an agonistic analog of α-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria.
- A randomized double-blind vehicle-controlled study to assess the safety and efficacy of afamelanotide in the treatment of vitiligo
- An open-label, dose-escalation study of afamelanotide in erythropoietic protoporphyria
- Oral polypodium leucotomos extract photoprotective activity in 57 patients with idiopathic photodermatoses
- Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics
- Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study
- Photoprotective activity of oral polypodium leucotomos extract in 25 patients with idiopathic photodermatoses
- Oral Polypodium leucotomos extract decreases ultraviolet-induced damage of human skin
- A new agent (hydrophilic fraction of polypodium leucotomos) for management of psoriasis
- Oral administration of a hydrophilic extract of Polypodium leucotomos for the prevention of polymorphic light eruption